Table of Contents Author Guidelines Submit a Manuscript
Scientifica
Volume 2012, Article ID 279731, 16 pages
http://dx.doi.org/10.6064/2012/279731
Review Article

Chronic Heart Failure: We Are Fighting the Battle, but Are We Winning the War?

1Cardiology Department, Royal Brisbane and Women’s Hospital, Butterfield Street, Herston, QLD 4006, Australia
2School of Medicine, University of Queensland, Brisbane, QLD 4006, Australia

Received 10 October 2012; Accepted 31 October 2012

Academic Editors: J. Alpert and K. Egstrup

Copyright © 2012 John J. Atherton. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. H. Curtis, D. J. Whellan, B. G. Hammill et al., “Incidence and prevalence of heart failure in elderly persons, 1994–2003,” Archives of Internal Medicine, vol. 168, no. 4, pp. 418–424, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. P. A. McCullough, E. F. Philbin, J. A. Spertus, S. Kaatz, K. R. Sandberg, and W. D. Weaver, “Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study,” Journal of the American College of Cardiology, vol. 39, no. 1, pp. 60–69, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. P. S. Jhund, K. MacIntyre, C. R. Simpson et al., “Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003. A population study of 5.1 million people,” Circulation, vol. 119, no. 4, pp. 515–523, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Schaufelberger, K. Swedberg, M. Köster, M. Rosén, and A. Rosengren, “Decreasing one-year mortality and hospitalization rates for heart failure in Sweden: data from the Swedish Hospital Discharge Registry 1988 to 2000,” European Heart Journal, vol. 25, no. 4, pp. 300–307, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. A. S. McLean, G. D. Eslick, and A. J. S. Coats, “The epidemiology of heart failure in Australia,” International Journal of Cardiology, vol. 118, no. 3, pp. 370–374, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. C. A. Wasywich, G. D. Gamble, G. A. Whalley, and R. N. Doughty, “Understanding changing patterns of survival and hospitalization for heart failure over two decades in New Zealand: utility of 'days alive and out of hospital' from epidemiological data,” European Journal of Heart Failure, vol. 12, no. 5, pp. 462–468, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. T. H. K. Teng, J. Finn, M. Hobbs, and J. Hung, “Heart failure: incidence, case fatality, and hospitalization rates in Western Australia between 1990 and 2005,” Circulation, vol. 3, no. 2, pp. 236–243, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Stewart, K. MacIntyre, M. M. C. MacLeod, A. E. M. Bailey, S. Capewell, and J. J. V. McMurray, “Trends in hospitalization for heart failure in Scotland, 1990–1996. An epidemic that has reached its peak?” European Heart Journal, vol. 22, no. 3, pp. 209–217, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. J. McMurray, T. McDonagh, C. E. Morrison, and H. J. Dargie, “Trends in hospitalization for heart failure in Scotland 1980–1990,” European Heart Journal, vol. 14, no. 9, pp. 1158–1162, 1993. View at Google Scholar · View at Scopus
  10. H. Ni, D. J. Nauman, and R. E. Hershberger, “Analysis of trends in hospitalizations for heart failure,” Journal of Cardiac Failure, vol. 5, no. 2, pp. 79–84, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. T. H. K. Teng, J. Hung, M. Knuiman et al., “Trends in long-term cardiovascular mortality and morbidity in men and women with heart failure of ischemic versus non-ischemic aetiology in Western Australia between 1990 and 2005,” International Journal of Cardiology, vol. 158, pp. 405–410, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. H. M. Blackledge, J. Tomlinson, and I. B. Squire, “Prognosis for patients newly admitted to hospital with heart failure: survival trends in 12 220 index admissions in Leicestershire 1993–2001,” Heart, vol. 89, no. 6, pp. 615–620, 2003. View at Google Scholar · View at Scopus
  13. V. L. Roger, S. A. Weston, M. M. Redfield et al., “Trends in heart failure incidence and survival in a community-based population,” Journal of the American Medical Association, vol. 292, no. 3, pp. 344–350, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Levy, S. Kenchaiah, M. Glarson et al., “Long-term trends in the incidence of and survival with heart failure,” The New England Journal of Medicine, vol. 347, no. 18, pp. 1397–1402, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. W. H. Barker, J. P. Mullooly, and W. Getchell, “Changing incidence and survival for heart failure in a well-defined older population, 1970–1974 and 1990–1994,” Circulation, vol. 113, no. 6, pp. 799–805, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. D. M. Lloyd-Jones, M. G. Larson, E. P. Leip et al., “Lifetime risk for developing congestive heart failure: the Framingham Heart Study,” Circulation, vol. 106, no. 24, pp. 3068–3072, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. G. S. Bleumink, A. M. Knetsch, M. C. J. M. Sturkenboom et al., “Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure—the Rotterdam Study,” European Heart Journal, vol. 25, no. 18, pp. 1614–1619, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Stewart, A. Jenkins, S. Buchan, A. McGuire, S. Capewell, and J. J. J. V. McMurray, “The current cost of heart failure to the National Health Service in the UK,” European Journal of Heart Failure, vol. 4, no. 3, pp. 361–371, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Liao, L. A. Allen, and D. J. Whellan, “Economic burden of heart failure in the elderly,” PharmacoEconomics, vol. 26, no. 6, pp. 447–462, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Braunschweig, M. R. Cowie, and A. Auricchio, “What are the costs of heart failure?” Europace, vol. 13, supplement 2, pp. ii13–ii17, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Jong, S. Yusuf, M. F. Rousseau, S. A. Ahn, and S. I. Bangdiwala, “Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study,” The Lancet, vol. 361, no. 9372, pp. 1843–1848, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. The SOLVD Investigattors, “Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions,” The New England Journal of Medicine, vol. 327, pp. 685–691, 1992. View at Publisher · View at Google Scholar
  23. R. J. Goldberg, J. Ciampa, D. Lessard, T. E. Meyer, and F. A. Spencer, “Long-term survival after heart failure: a contemporary population-based perspective,” Archives of Internal Medicine, vol. 167, no. 5, pp. 490–496, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Stewart, K. MacIntyre, D. J. Hole, S. Capewell, and J. J. V. McMurray, “More 'malignant' than cancer? Five-year survival following a first admission for heart failure,” European Journal of Heart Failure, vol. 3, no. 3, pp. 315–322, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Bueno, J. S. Ross, Y. Wang et al., “Trends in length of stay and short-term outcomes among medicare patients hospitalized for heart failure, 1993–2006,” Journal of the American Medical Association, vol. 303, no. 21, pp. 2141–2147, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. S. F. Jencks, M. V. Williams, and E. A. Coleman, “Rehospitalizations among patients in the medicare fee-for-service program,” The New England Journal of Medicine, vol. 360, no. 14, pp. 1418–1428, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. D. E. Feldman, C. Thivierge, L. Guérard et al., “Changing trends in mortality and admissions to hospital for elderly patients with congestive heart failure in Montreal,” Canadian Medical Association Journal, vol. 165, no. 8, pp. 1033–1036, 2001. View at Google Scholar · View at Scopus
  28. M. Shafazand, M. Schaufelberger, G. Lappas, K. Swedberg, and A. Rosengren, “Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987–2003 from the Swedish hospital discharge registry,” European Heart Journal, vol. 30, no. 6, pp. 671–678, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. D. S. Lee, M. M. Mamdani, P. C. Austin et al., “Trends in heart failure outcomes and pharmacotherapy: 1992 to 2000,” American Journal of Medicine, vol. 116, no. 9, pp. 581–589, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Fang, G. A. Mensah, J. B. Croft, and N. L. Keenan, “Heart Failure-Related Hospitalization in the U.S., 1979 to 2004,” Journal of the American College of Cardiology, vol. 52, no. 6, pp. 428–434, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Ni and R. E. Hershberger, “Was the decreasing trend in hospital mortality from heart failure attributable to improved hospital care? The Oregon experience, 1991–1995,” American Journal of Managed Care, vol. 5, no. 9, pp. 1105–1115, 1999. View at Google Scholar · View at Scopus
  32. C. A. Polanczyk, L. E. P. Rohde, G. W. Dec, and T. DiSalvo, “Ten-year trends in hospital care for congestive heart failure: improved outcomes and increased use of resources,” Archives of Internal Medicine, vol. 160, no. 3, pp. 325–332, 2000. View at Google Scholar · View at Scopus
  33. J. V. Tu, L. Nardi, J. Fang, J. Liu, L. Khalid, and H. Johansen, “National trends in rates of death and hospital admissions related to acute myocardial infarction, heart failure and stroke, 1994–2004,” Canadian Medical Association Journal, vol. 180, no. 13, pp. E118–E125, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. T. H. K. Teng, J. Hung, and J. Finn, “The effect of evidence-based medication use on long-term survival in patients hospitalised for heart failure in Western Australia,” Medical Journal of Australia, vol. 192, no. 6, pp. 306–310, 2010. View at Google Scholar · View at Scopus
  35. T. E. Owan, D. O. Hodge, R. M. Herges, S. J. Jacobsen, V. L. Roger, and M. M. Redfield, “Trends in prevalence and outcome of heart failure with preserved ejection fraction,” The New England Journal of Medicine, vol. 355, no. 3, pp. 251–259, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. “The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis,” European Heart Journal, vol. 33, pp. 1750–1757, 2012.
  37. J. B. Somaratne, C. Berry, J. J. V. McMurray, K. K. Poppe, R. N. Doughty, and G. A. Whalley, “The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature-based meta-analysis,” European Journal of Heart Failure, vol. 11, no. 9, pp. 855–862, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. D. S. Lee, P. Gona, R. S. Vasan et al., “Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute,” Circulation, vol. 119, no. 24, pp. 3070–3077, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. R. S. Bhatia, J. V. Tu, D. S. Lee et al., “Outcome of heart failure with preserved ejection fraction in a population-based study,” The New England Journal of Medicine, vol. 355, no. 3, pp. 260–269, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. J. S. Gottdiener, R. L. McClelland, R. Marshall et al., “Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The cardiovascular health study,” Annals of Internal Medicine, vol. 137, no. 8, pp. 631–639, 2002. View at Google Scholar · View at Scopus
  41. J. F. Setaro, R. Soufer, M. S. Remetz, R. A. Perlmutter, and B. L. Zaret, “Long-term outcome in patients with congestive heart failure and intact systolic left ventricular performance,” American Journal of Cardiology, vol. 69, no. 14, pp. 1212–1216, 1992. View at Publisher · View at Google Scholar · View at Scopus
  42. B. R. Davis, J. B. Kostis, L. M. Simpson et al., “Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial,” Circulation, vol. 118, no. 22, pp. 2259–2267, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. R. S. Vasan, M. G. Larson, E. J. Benjamin, J. C. Evans, C. K. Reiss, and D. Levy, “Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort,” Journal of the American College of Cardiology, vol. 33, no. 7, pp. 1948–1955, 1999. View at Publisher · View at Google Scholar · View at Scopus
  44. J. B. Braunstein, G. F. Anderson, G. Gerstenblith et al., “Noncardiac comorbidity increases preventable hospitalizations and mortality among medicare beneficiaries with chronic heart failure,” Journal of the American College of Cardiology, vol. 42, no. 7, pp. 1226–1233, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. S. M. Dunlay, M. M. Redfield, S. A. Weston et al., “Hospitalizations after heart failure diagnosis. A community perspective,” Journal of the American College of Cardiology, vol. 54, no. 18, pp. 1695–1702, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. H. Krum, M. V. Jelinek, S. Stewart, A. Sindone, and J. Atherton, “2011 Update to National Heart Foundation of Australian and Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006,” Medical Journal of Australia, vol. 194, no. 8, pp. 405–409, 2011. View at Google Scholar · View at Scopus
  47. S. A. Hunt, W. T. Abraham, M. H. Chin et al., “ACC/AHA, 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society,” Circulation, vol. 112, pp. e154–e235, 2005. View at Google Scholar
  48. K. Swedberg, J. Cleland, H. Dargie et al., “Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology,” European Heart Journal, vol. 26, pp. 1115–1140, 2005. View at Google Scholar
  49. J. J. McMurray, S. Adamopoulos, S. D. Anker et al., “ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC,” European Heart Journal, vol. 33, pp. 1787–1847, 2012. View at Google Scholar
  50. H. Krum, M. V. Jelinek, S. Stewart, A. Sindone, and J. Atherton, “2011 Update to National Heart Foundation of Australian and Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006,” Medical Journal of Australia, vol. 194, no. 8, pp. 405–409, 2011. View at Google Scholar · View at Scopus
  51. M. Jessup, W. T. Abraham, D. E. Casey et al., “2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation,” Circulation, vol. 119, no. 14, pp. 1977–2016, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Yusuf, “Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure,” The New England Journal of Medicine, vol. 325, no. 5, pp. 293–302, 1991. View at Google Scholar · View at Scopus
  53. L. Køber, C. Torp-Pedersen, J. E. Carlsen et al., “A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction,” The New England Journal of Medicine, vol. 333, no. 25, pp. 1670–1676, 1995. View at Publisher · View at Google Scholar · View at Scopus
  54. M. A. Pfeffer, J. J. V. McMurray, E. J. Velazquez et al., “Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both,” The New England Journal of Medicine, vol. 349, no. 20, pp. 1893–1906, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. M. A. Pfeffer, E. Braunwald, L. A. Moye et al., “Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction—results of the survival and ventricular enlargement trial,” The New England Journal of Medicine, vol. 327, no. 10, pp. 669–677, 1992. View at Google Scholar · View at Scopus
  56. H. J. Dargie, “Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial,” The Lancet, vol. 357, no. 9266, pp. 1385–1390, 2001. View at Publisher · View at Google Scholar · View at Scopus
  57. W. S. Colucci, T. J. Kolias, K. F. Adams et al., “Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) Trial,” Circulation, vol. 116, no. 1, pp. 49–56, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. M. D. Flather, S. Yusuf, L. Køber et al., “Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients,” The Lancet, vol. 355, no. 9215, pp. 1575–1581, 2000. View at Google Scholar · View at Scopus
  59. M. Packer, A. J. S. Coats, M. B. Fowler et al., “Effect of carvedilol on survival in severe chronic heart failure,” The New England Journal of Medicine, vol. 344, no. 22, pp. 1651–1658, 2001. View at Publisher · View at Google Scholar · View at Scopus
  60. “Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF),” The Lancet, vol. 353, pp. 2001–2007, 1999.
  61. H. J. Dargie and P. Lechat, “The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial,” The Lancet, vol. 353, no. 9146, pp. 9–13, 1999. View at Publisher · View at Google Scholar · View at Scopus
  62. F. Zannad, J. J. V. McMurray, H. Krum et al., “Eplerenone in patients with systolic heart failure and mild symptoms,” The New England Journal of Medicine, vol. 364, no. 1, pp. 11–21, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. B. Pitt, W. Remme, F. Zannad et al., “Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction,” The New England Journal of Medicine, vol. 348, no. 14, pp. 1309–1321, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. B. Pitt, F. Zannad, W. J. Remme et al., “The effect of spironolactone on morbidity and mortality in patients with severe heart failure,” The New England Journal of Medicine, vol. 341, no. 10, pp. 709–717, 1999. View at Publisher · View at Google Scholar · View at Scopus
  65. K. Swedberg, U. Idanpaan-Heikkila, and J. Remes, “Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group,” The New England Journal of Medicine, vol. 316, no. 23, pp. 1429–1435, 1987. View at Google Scholar · View at Scopus
  66. B. Pitt, P. A. Poole-Wilson, R. Segal et al., “Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II,” The Lancet, vol. 355, no. 9215, pp. 1582–1587, 2000. View at Google Scholar · View at Scopus
  67. C. B. Granger, J. J. V. McMurray, S. Yusuf et al., “Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial,” The Lancet, vol. 362, no. 9386, pp. 772–776, 2003. View at Publisher · View at Google Scholar · View at Scopus
  68. J. J. V. McMurray, J. Östergren, K. Swedberg et al., “Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial,” The Lancet, vol. 362, no. 9386, pp. 767–771, 2003. View at Publisher · View at Google Scholar · View at Scopus
  69. R. J. MacFadyen, A. F. C. Lee, J. J. Morton, S. D. Pringle, and A. D. Struthers, “How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?” Heart, vol. 82, no. 1, pp. 57–61, 1999. View at Google Scholar · View at Scopus
  70. C. Borghi, S. Boschi, E. Ambrosioni, G. Melandri, A. Branzi, and B. Magnani, “Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ace inhibitors,” Journal of Clinical Pharmacology, vol. 33, no. 1, pp. 40–45, 1993. View at Google Scholar · View at Scopus
  71. D. N. Juurlink, M. M. Mamdani, D. S. Lee et al., “Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study,” The New England Journal of Medicine, vol. 351, pp. 543–551, 2004. View at Google Scholar
  72. L. Wei, A. D. Struthers, T. Fahey, A. D. Watson, and T. M. Macdonald, “Spironolactone use and renal toxicity: population based longitudinal analysis,” British Medical Journal, vol. 340, article c1768, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. K. Swedberg, M. Komajda, M. Bohm, Ivabradine a et al., “nd outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study,” The Lancet, vol. 376, pp. 875–885, 2010. View at Publisher · View at Google Scholar
  74. L. Tavazzi, A. P. Maggioni, R. Marchioli et al., “Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 372, no. 9645, pp. 1223–1230, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. S. D. Anker, J. C. Colet, G. Filippatos et al., “Ferric carboxymaltose in patients with heart failure and iron deficiency,” The New England Journal of Medicine, vol. 361, no. 25, pp. 2436–2448, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. A. L. Taylor, S. Ziesche, C. Yancy et al., “Combination of isosorbide dinitrate and hydralazine in blacks with heart failure,” The New England Journal of Medicine, vol. 351, no. 20, pp. 2049–2141, 2004. View at Publisher · View at Google Scholar · View at Scopus
  77. The Digitalis Investigation Group, “The effect of digoxin on mortality and morbidity in patients with heart failure,” The New England Journal of Medicine, vol. 336, pp. 525–533, 1997. View at Google Scholar
  78. G. H. Bardy, K. L. Lee, D. B. Mark et al., “Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure,” The New England Journal of Medicine, vol. 352, pp. 225–237, 2005. View at Google Scholar
  79. A. J. Moss, W. Zareba, W. Jackson Hall et al., “Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction,” The New England Journal of Medicine, vol. 346, no. 12, pp. 877–883, 2002. View at Publisher · View at Google Scholar · View at Scopus
  80. S. M. Al-Khatib, K. J. Anstrom, E. L. Eisenstein et al., “Clinical and economic implications of the multicenter automatic defibrillator implantation trial-II,” Annals of Internal Medicine, vol. 142, no. 8, pp. 593–600, 2005. View at Google Scholar · View at Scopus
  81. G. D. Sanders, M. A. Hlatky, and D. K. Owens, “Cost-effectiveness of implantable cardioverter-defibrillators,” The New England Journal of Medicine, vol. 353, no. 14, pp. 1471–1480, 2005. View at Publisher · View at Google Scholar · View at Scopus
  82. J. Zwanziger, W. J. Hall, A. W. Dick et al., “The cost effectiveness of implantable cardioverter-defibrillators. Results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II,” Journal of the American College of Cardiology, vol. 47, no. 11, pp. 2310–2318, 2006. View at Publisher · View at Google Scholar · View at Scopus
  83. D. B. Mark, C. L. Nelson, K. J. Anstrom et al., “Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT),” Circulation, vol. 114, no. 2, pp. 135–142, 2006. View at Publisher · View at Google Scholar · View at Scopus
  84. MSAC Assessment Report: Implantable cardioverter defibrillators for prevention of sudden death. Medical Services Advisory Committee, Canberra, Australia 2006, http://www.msac.gov.au/internet/msac/publishing.nsf/Content/8FD1D98FE64C8A2FCA2575AD0082FD8F/$File/MSAC%20Ref%2032%20-%20ICDs.pdf.
  85. D. Farwell, N. R. Patel, A. Hall, S. Ralph, and A. N. Sulke, “How many people with heart failure are appropriate for biventricular resynchronization?” European Heart Journal, vol. 21, no. 15, pp. 1246–1250, 2000. View at Publisher · View at Google Scholar · View at Scopus
  86. S. Cazeau, C. Leclercq, T. Lavergne et al., “Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay,” The New England Journal of Medicine, vol. 344, no. 12, pp. 873–880, 2001. View at Publisher · View at Google Scholar · View at Scopus
  87. J. B. Young, W. T. Abraham, A. L. Smith et al., “Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial,” Journal of the American Medical Association, vol. 289, no. 20, pp. 2685–2694, 2003. View at Publisher · View at Google Scholar · View at Scopus
  88. W. T. Abraham, W. G. Fisher, A. L. Smith et al., “Cardiac resynchronization in chronic heart failure,” The New England Journal of Medicine, vol. 346, pp. 1845–1853, 2002. View at Google Scholar
  89. A. Auricchio, C. Stellbrink, S. Sack et al., “Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay,” Journal of the American College of Cardiology, vol. 39, no. 12, pp. 2026–2033, 2002. View at Publisher · View at Google Scholar · View at Scopus
  90. C. Linde, C. Leclercq, S. Rex et al., “Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation In Cardiomyopathy (MUSTIC) study,” Journal of the American College of Cardiology, vol. 40, no. 1, pp. 111–118, 2002. View at Publisher · View at Google Scholar · View at Scopus
  91. N. Freemantle, P. Tharmanathan, M. J. Calvert, W. T. Abraham, J. Ghosh, and J. G. F. Cleland, “Cardiac resynchronisation for patients with heart failure due to left ventricular systolic dysfunction—a systematic review and meta-analysis,” European Journal of Heart Failure, vol. 8, no. 4, pp. 433–440, 2006. View at Publisher · View at Google Scholar · View at Scopus
  92. A. S. L. Tang, G. A. Wells, M. Talajic et al., “Cardiac-resynchronization therapy for mild-to-moderate heart failure,” The New England Journal of Medicine, vol. 363, no. 25, pp. 2385–2395, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. G. Wells, R. Parkash, J. S. Healey et al., “Cardiac resynchronization therapy: a meta-analysis of randomized controlled trials,” Canadian Medical Association Journal, vol. 183, no. 4, pp. 421–429, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. M. R. Bristow, L. A. Saxon, J. Boehmer et al., “Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure,” The New England Journal of Medicine, vol. 350, no. 21, pp. 2140–2150, 2004. View at Publisher · View at Google Scholar · View at Scopus
  95. J. G. F. Cleland, J. C. Daubert, E. Erdmann et al., “The effect of cardiac resynchronization on morbidity and mortality in heart failure,” The New England Journal of Medicine, vol. 352, no. 15, pp. 1539–1549, 2005. View at Publisher · View at Google Scholar · View at Scopus
  96. G. C. Fonarow, J. T. Heywood, P. A. Heidenreich, M. Lopatin, and C. W. Yancy, “Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE),” American Heart Journal, vol. 153, no. 6, pp. 1021–1028, 2007. View at Publisher · View at Google Scholar · View at Scopus
  97. M. S. Nieminen, D. Brutsaert, K. Dickstein et al., “EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population,” European Heart Journal, vol. 27, no. 22, pp. 2725–2736, 2006. View at Publisher · View at Google Scholar · View at Scopus
  98. J. J. Atherton, C. S. Hayward, W. A. Wan Ahmad et al., “Patient characteristics from a regional multicenter database of acute decompensated heart failure in Asia Pacific (ADHERE International-Asia Pacific),” Journal of Cardiac Failure, vol. 18, pp. 82–88, 2012. View at Google Scholar
  99. G. C. Fonarow, W. T. Abraham, N. M. Albert et al., “Association between performance measures and clinical outcomes for patients hospitalized with heart failure,” Journal of the American Medical Association, vol. 297, no. 1, pp. 61–70, 2007. View at Publisher · View at Google Scholar · View at Scopus
  100. A. Michalsen, G. König, and W. Thimme, “Preventable causative factors leading to hospital admission with decompensated heart failure,” Heart, vol. 80, no. 5, pp. 437–441, 1998. View at Google Scholar · View at Scopus
  101. F. A. McAlister, S. Stewart, S. Ferrua, and J. J. J. V. McMurray, “Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials,” Journal of the American College of Cardiology, vol. 44, no. 4, pp. 810–819, 2004. View at Publisher · View at Google Scholar · View at Scopus
  102. R. Holland, J. Battersby, I. Harvey, E. Lenaghan, J. Smith, and L. Hay, “Systematic review of multidisciplinary interventions in heart failure,” Heart, vol. 91, no. 7, pp. 899–906, 2005. View at Publisher · View at Google Scholar · View at Scopus
  103. M. W. Rich, V. Beckham, C. Wittenberg, C. L. Leven, K. E. Freedland, and R. M. Carney, “A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure,” The New England Journal of Medicine, vol. 333, no. 18, pp. 1190–1195, 1995. View at Publisher · View at Google Scholar · View at Scopus
  104. S. Stewart, J. E. Marley, and J. D. Horowitz, “Effects of a multidisciplinary, home-based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study,” The Lancet, vol. 354, no. 9184, pp. 1077–1083, 1999. View at Publisher · View at Google Scholar · View at Scopus
  105. C. O. Phillips, S. M. Wright, D. E. Kern, R. M. Singa, S. Shepperd, and H. R. Rubin, “Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis,” Journal of the American Medical Association, vol. 291, no. 11, pp. 1358–1367, 2004. View at Publisher · View at Google Scholar · View at Scopus
  106. H. C. Wijeysundera, M. MacHado, X. Wang et al., “Cost-effectiveness of specialized multidisciplinary heart failure clinics in Ontario, Canada,” Value in Health, vol. 13, no. 8, pp. 915–921, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. D. S. F. Yu, D. R. Thompson, and D. T. F. Lee, “Disease management programmes for older people with heart failure: crucial characteristics which improve post-discharge outcomes,” European Heart Journal, vol. 27, no. 5, pp. 596–612, 2006. View at Publisher · View at Google Scholar · View at Scopus
  108. National Heart Foundation of Australia, Multidisciplinary care for people with chronic heart failure, Principles and recommendations for best practice, National Heart Foundation of Australia, Melbourne, Australia, 2010, http://www.heartfoundation.org.au/SiteCollectionDocuments/Multidisciplinary-care-for-people-with-CHF.pdf.
  109. J. Suarez, J. P. Piccini, L. Liang et al., “International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation,” American Heart Journal, vol. 163, pp. 804–811, 2012. View at Google Scholar
  110. G. C. Fonarow, C. W. Yancy, and J. T. Heywood, “Adherence to heart failure quality-of-care indicators in US hospitals: analysis of the ADHERE registry,” Archives of Internal Medicine, vol. 165, no. 13, pp. 1469–1477, 2005. View at Publisher · View at Google Scholar · View at Scopus
  111. I. A. Scott, C. P. Denaro, J. L. Flores et al., “Quality of care of patients hospitalized with congestive heart failure,” Internal Medicine Journal, vol. 33, no. 4, pp. 140–151, 2003. View at Publisher · View at Google Scholar · View at Scopus
  112. N. M. Albert, C. W. Yancy, L. Liang et al., “Use of aldosterone antagonists in heart failure,” Journal of the American Medical Association, vol. 302, no. 15, pp. 1658–1665, 2009. View at Publisher · View at Google Scholar · View at Scopus
  113. D. S. Lee, J. V. Tu, D. N. Juurlink et al., “Risk-treatment mismatch in the pharmacotherapy of heart failure,” Journal of the American Medical Association, vol. 294, no. 10, pp. 1240–1247, 2005. View at Publisher · View at Google Scholar · View at Scopus
  114. J. P. Piccini, A. F. Hernandez, D. Dai et al., “Use of cardiac resynchronization therapy in patients hospitalized with heart failure,” Circulation, vol. 118, no. 9, pp. 926–933, 2008. View at Publisher · View at Google Scholar · View at Scopus
  115. J. G. F. Cleland, T. McDonagh, A. S. Rigby, A. Yassin, T. Whittaker, and H. J. Dargie, “The national heart failure audit for England and Wales 2008-2009,” Heart, vol. 97, no. 11, pp. 876–886, 2011. View at Publisher · View at Google Scholar · View at Scopus
  116. H. Krum, A. M. Tonkin, R. Currie, R. Djundjek, and C. Johnston, “Chronic heart failure in Australian general practice: the Cardiac Awareness Survey and Evaluation (CASE) study,” Medical Journal of Australia, vol. 174, no. 9, pp. 439–444, 2001. View at Google Scholar · View at Scopus
  117. J. G. F. Cleland, A. Cohen-Solal, J. C. Aguilar et al., “Management of heart failure in primary care (the Improvement of Heart Failure Programme): an international survey,” The Lancet, vol. 360, no. 9346, pp. 1631–1639, 2002. View at Publisher · View at Google Scholar · View at Scopus
  118. R. S. Stafford and D. C. Radley, “The underutilization of cardiac medications of proven benefit, 1990 to 2002,” Journal of the American College of Cardiology, vol. 41, no. 1, pp. 56–61, 2003. View at Publisher · View at Google Scholar · View at Scopus
  119. M. Komajda, P. Lapuerta, N. Hermans et al., “Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey,” European Heart Journal, vol. 26, no. 16, pp. 1653–1659, 2005. View at Publisher · View at Google Scholar · View at Scopus
  120. G. C. Fonarow, C. W. Yancy, N. M. Albert et al., “Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF,” Circulation Heart failure, vol. 1, no. 2, pp. 98–106, 2008. View at Publisher · View at Google Scholar · View at Scopus
  121. G. C. Fonarow, W. T. Abraham, N. M. Albert et al., “Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF),” Archives of Internal Medicine, vol. 167, no. 14, pp. 1493–1502, 2007. View at Publisher · View at Google Scholar · View at Scopus
  122. K. F. Adams Jr., G. C. Fonarow, C. L. Emerman et al., “Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE),” American Heart Journal, vol. 149, no. 2, pp. 209–216, 2005. View at Publisher · View at Google Scholar · View at Scopus
  123. C. Tribouilloy, D. Rusinaru, H. Mahjoub, T. Goissen, F. Lévy, and M. Peltier, “Impact of echocardiography in patients hospitalized for heart failure: a prospective observational study,” Archives of Cardiovascular Diseases, vol. 101, no. 7-8, pp. 465–473, 2008. View at Publisher · View at Google Scholar · View at Scopus
  124. M. J. Calvert, A. Shankar, R. J. McManus, R. Ryan, and N. Freemantle, “Evaluation of the management of heart failure in primary care,” Family Practice, vol. 26, no. 2, pp. 145–153, 2009. View at Publisher · View at Google Scholar · View at Scopus
  125. M. Komajda, F. Follath, K. Swedberg et al., “The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment,” European Heart Journal, vol. 24, no. 5, pp. 464–474, 2003. View at Publisher · View at Google Scholar · View at Scopus
  126. G. Gelbrich, F. Edelmann, S. Inkrot et al., “Is target dose the treatment target? Uptitrating beta-blockers for heart failure in the elderly,” International Journal of Cardiology, vol. 155, pp. 160–166, 2012. View at Publisher · View at Google Scholar
  127. M. B. Fowler, S. R. Lottes, J. J. Nelson et al., “β-Blocker dosing in community-based treatment of heart failure,” American Heart Journal, vol. 153, no. 6, pp. 1029–1036, 2007. View at Publisher · View at Google Scholar · View at Scopus
  128. G. C. Fonarow, W. T. Abraham, N. M. Albert et al., “Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from organized program to initiate lifesaving treatment in hospitalized patients with heart failure),” American Journal of Cardiology, vol. 102, no. 11, pp. 1524–1529, 2008. View at Publisher · View at Google Scholar · View at Scopus
  129. G. H. Gislason, J. N. Rasmussen, S. Z. Abildstrom et al., “Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes,” Circulation, vol. 116, no. 7, pp. 737–744, 2007. View at Publisher · View at Google Scholar · View at Scopus
  130. J. A. Franciosa, B. M. Massie, M. A. Lukas et al., “β-blocker therapy for heart failure outside the clinical trial setting: Findings of a community-based registry,” American Heart Journal, vol. 148, no. 4, pp. 718–726, 2004. View at Publisher · View at Google Scholar · View at Scopus
  131. H. D. Düngen, S. Apostolović, S. Inkrot et al., “Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: The CIBIS-ELD trial,” European Journal of Heart Failure, vol. 13, no. 6, pp. 670–680, 2011. View at Publisher · View at Google Scholar · View at Scopus
  132. F. Gustafsson, M. Schou, L. Videbæk et al., “Treatment with beta-blockers in nurse-led heart failure clinics: Titration efficacy and predictors of failure,” European Journal of Heart Failure, vol. 9, no. 9, pp. 910–916, 2007. View at Publisher · View at Google Scholar · View at Scopus
  133. A. Driscoll, H. Krum, R. Wolfe, and A. Tonkin, “Nurse-led titration of β-adrenoreceptor blocking agents in chronic heart failure patients in the community,” Journal of Cardiac Failure, vol. 17, no. 3, pp. 224–230, 2011. View at Publisher · View at Google Scholar · View at Scopus
  134. P. A. Mehta, S. McDonagh, P. A. Poole-Wilson, R. Grocott-Mason, and S. W. Dubrey, “Heart failure in a district general hospital: are target doses of beta-blockers realistic?” QJM: Monthly Journal of the Association of Physicians, vol. 97, no. 3, pp. 133–139, 2004. View at Publisher · View at Google Scholar · View at Scopus
  135. A. Jain, P. Mills, L. M. Nunn et al., “Success of a multidisciplinary heart failure clinic for initiation and up-titration of key therapeutic agents,” European Journal of Heart Failure, vol. 7, no. 3, pp. 405–410, 2005. View at Publisher · View at Google Scholar · View at Scopus
  136. M. Lainscak, C. Moullet, N. Schön, and M. Tendera, “Treatment of chronic heart failure with carvedilol in daily practice: the SATELLITE survey experience,” International Journal of Cardiology, vol. 122, no. 2, pp. 149–155, 2007. View at Publisher · View at Google Scholar · View at Scopus
  137. P. Tandon, F. A. McAlister, R. T. Tsuyuki et al., “The use of β-blockers in a tertiary care heart failure clinic: dosing, tolerance, and outcomes,” Archives of Internal Medicine, vol. 164, no. 7, pp. 769–774, 2004. View at Publisher · View at Google Scholar · View at Scopus
  138. G. C. Fonarow, N. M. Albert, A. B. Curtis et al., “Associations between outpatient heart failure process-of-care measures and mortality,” Circulation, vol. 123, no. 15, pp. 1601–1610, 2011. View at Publisher · View at Google Scholar · View at Scopus
  139. S. A. Hunt, W. T. Abraham, M. H. Chin et al., “2009 focused update incorporated into the ACC/AHA, 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation,” Circulation, vol. 119, pp. e391–e479, 2009. View at Google Scholar
  140. J. J. Atherton, “Stage B heart failure: rationale for screening,” Heart Failure Clinics, vol. 8, pp. 273–283, 2012. View at Publisher · View at Google Scholar
  141. T. H. K. Teng, J. Finn, J. Hung, E. Geelhoed, and M. Hobbs, “A validation study: how effective is the Hospital Morbidity Data as a surveillance tool for heart failure in Western Australia?” Australian and New Zealand Journal of Public Health, vol. 32, no. 5, pp. 405–407, 2008. View at Publisher · View at Google Scholar · View at Scopus
  142. J. Langley, S. Stephenson, C. Thorpe, and G. Davie, “Accuracy of injury coding under ICD-9 for New Zealand public hospital discharges,” Injury Prevention, vol. 12, no. 1, pp. 58–61, 2006. View at Publisher · View at Google Scholar · View at Scopus
  143. T. Kümler, G. H. Gislason, V. Kirk et al., “Accuracy of a heart failure diagnosis in administrative registers,” European Journal of Heart Failure, vol. 10, no. 7, pp. 658–660, 2008. View at Publisher · View at Google Scholar · View at Scopus
  144. C. W. Yancy, M. Lopatin, L. W. Stevenson, T. De Marco, and G. C. Fonarow, “Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database,” Journal of the American College of Cardiology, vol. 47, pp. 76–84, 2006. View at Google Scholar
  145. G. C. Fonarow, W. G. Stough, W. T. Abraham et al., “Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure. A report from the OPTIMIZE-HF registry,” Journal of the American College of Cardiology, vol. 50, no. 8, pp. 768–777, 2007. View at Publisher · View at Google Scholar · View at Scopus
  146. T. E. Owan and M. M. Redfield, “Epidemiology of diastolic heart failure,” Progress in Cardiovascular Diseases, vol. 47, no. 5, pp. 320–332, 2005. View at Publisher · View at Google Scholar · View at Scopus
  147. C. S. P. Lam, E. Donal, E. Kraigher-Krainer, and R. S. Vasan, “Epidemiology and clinical course of heart failure with preserved ejection fraction,” European Journal of Heart Failure, vol. 13, no. 1, pp. 18–28, 2011. View at Publisher · View at Google Scholar · View at Scopus
  148. M. J. Lenzen, E. Boersma, W. J. M. Scholte Op Reimer et al., “Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure,” European Heart Journal, vol. 26, no. 24, pp. 2706–2713, 2005. View at Publisher · View at Google Scholar · View at Scopus
  149. W. A. Gattis, C. M. O'Connor, D. S. Gallup, V. Hasselblad, and M. Gheorghiade, “Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the initiation management predischarge: process for assessment of carvedilol therapy in heart failure (IMPACT-HF) trial,” Journal of the American College of Cardiology, vol. 43, no. 9, pp. 1534–1541, 2004. View at Publisher · View at Google Scholar · View at Scopus
  150. L. Baruch and R. A. Phillips, “Quality: the need for intelligent efforts,” Archives of Internal Medicine, vol. 165, no. 13, pp. 1455–1456, 2005. View at Publisher · View at Google Scholar · View at Scopus
  151. G. C. Fonarow, “Improving quality of care and outcomes for heart failure: role of registries,” Circulation Journal, vol. 75, no. 8, pp. 1783–1790, 2011. View at Publisher · View at Google Scholar · View at Scopus
  152. G. C. Fonarow, N. M. Albert, A. B. Curtis et al., “Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the registry to improve the use of evidence-based heart failure therapies in the outpatient setting (IMPROVE HF),” Circulation, vol. 122, no. 6, pp. 585–596, 2010. View at Publisher · View at Google Scholar · View at Scopus
  153. P. A. Heidenreich, W. R. Lewis, K. A. LaBresh, L. H. Schwamm, and G. C. Fonarow, “Hospital performance recognition with the Get With The Guidelines Program and mortality for acute myocardial infarction and heart failure,” American Heart Journal, vol. 158, no. 4, pp. 546–553, 2009. View at Publisher · View at Google Scholar · View at Scopus
  154. J. J. Atherton, A. Hickey, and J. Suna, “Striving to achieve best practice in heart failure disease management,” BMJ Quality and Safety, vol. 21, article 263, 2012. View at Google Scholar
  155. H. Krum, J. Hill, F. Fruhwald et al., “Tolerability of beta-blockers in elderly patients with chronic heart failure: the COLA II study,” European Journal of Heart Failure, vol. 8, no. 3, pp. 302–307, 2006. View at Publisher · View at Google Scholar · View at Scopus
  156. I. Ekman, B. Fagerberg, B. Andersson, G. Matejka, and B. Persson, “Can treatment with angiotensin-converting enzyme inhibitors in elderly patients with moderate to severe chronic heart failure be improved by a nurse-monitored structured care program? A randomized controlled trial,” Heart and Lung, vol. 32, no. 1, pp. 3–9, 2003. View at Publisher · View at Google Scholar · View at Scopus
  157. M. Ansari, M. G. Shlipak, P. A. Heidenreich et al., “Improving guideline adherence: a randomized trial evaluating strategies to increase β-blocker use in heart failure,” Circulation, vol. 107, no. 22, pp. 2799–2804, 2003. View at Publisher · View at Google Scholar · View at Scopus
  158. A. Hickey, J. Suna, L. Marquart, C. P. Denaro, G. Javorsky, and J. Atherton, “Predictors of therapeutic dose achievement in the management of heart failure,” Heart Lung Circulation, vol. 21, supplement 1, pp. S87–S88, 2012. View at Google Scholar
  159. S. C. Inglis, R. A. Clark, F. A. McAlister et al., “Structured telephone support or telemonitoring programmes for patients with chronic heart failure,” Cochrane Database of Systematic Reviews, vol. 8, Article ID CD007228, 2010. View at Google Scholar · View at Scopus
  160. R. A. Clark, S. C. Inglis, F. A. McAlister, J. G. F. Cleland, and S. Stewart, “Telemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and meta-analysis,” British Medical Journal, vol. 334, no. 7600, pp. 942–945, 2007. View at Publisher · View at Google Scholar · View at Scopus
  161. S. I. Chaudhry, J. A. Mattera, J. P. Curtis et al., “Telemonitoring in patients with heart failure,” The New England Journal of Medicine, vol. 363, no. 24, pp. 2301–2309, 2010. View at Publisher · View at Google Scholar · View at Scopus
  162. F. Koehler, S. Winkler, M. Schieber et al., “Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study,” Circulation, vol. 123, no. 17, pp. 1873–1880, 2011. View at Publisher · View at Google Scholar · View at Scopus
  163. S. I. Chaudhry, Y. Wang, J. Concato, T. M. Gill, and H. M. Krumholz, “Patterns of weight change preceding hospitalization for heart failure,” Circulation, vol. 116, no. 14, pp. 1549–1554, 2007. View at Publisher · View at Google Scholar · View at Scopus
  164. J. Zhang, K. M. Goode, P. E. Cuddihy, and J. G. F. Cleland, “Predicting hospitalization due to worsening heart failure using daily weight measurement: analysis of the Trans-European Network-Home-Care Management System (TEN-HMS) study,” European Journal of Heart Failure, vol. 11, no. 4, pp. 420–427, 2009. View at Publisher · View at Google Scholar · View at Scopus
  165. J. Lewin, M. Ledwidge, C. O'Loughlin, C. McNally, and K. McDonald, “Clinical deterioration in established heart failure: what is the value of BNP and weight gain in aiding diagnosis?” European Journal of Heart Failure, vol. 7, no. 6, pp. 953–957, 2005. View at Publisher · View at Google Scholar · View at Scopus
  166. P. Porapakkham, P. Porapakkham, H. Zimmet, B. Billah, and H. Krum, “B-type natriuretic peptide-guided heart failure therapy: a meta-analysis,” Archives of Internal Medicine, vol. 170, no. 6, pp. 507–514, 2010. View at Google Scholar · View at Scopus
  167. G. M. Felker, V. Hasselblad, A. F. Hernandez, and C. M. O'Connor, “Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials,” American Heart Journal, vol. 158, no. 3, pp. 422–430, 2009. View at Publisher · View at Google Scholar · View at Scopus
  168. C. M. Yu, L. Wang, E. Chau et al., “Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization,” Circulation, vol. 112, no. 6, pp. 841–848, 2005. View at Publisher · View at Google Scholar · View at Scopus
  169. C. Ypenburg, J. J. Bax, E. E. van der Wall, M. J. Schalij, and L. van Erven, “Intrathoracic impedance monitoring to predict decompensated heart failure,” American Journal of Cardiology, vol. 99, no. 4, pp. 554–557, 2007. View at Publisher · View at Google Scholar · View at Scopus
  170. P. B. Adamson, A. Magalski, F. Braunschweig et al., “Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system,” Journal of the American College of Cardiology, vol. 41, no. 4, pp. 565–571, 2003. View at Publisher · View at Google Scholar · View at Scopus
  171. M. R. Zile, T. D. Bennett, S. M. S. John et al., “Transition from chronic compensated to acute d compensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures,” Circulation, vol. 118, no. 14, pp. 1433–1441, 2008. View at Publisher · View at Google Scholar · View at Scopus
  172. J. Ritzema, R. Troughton, I. Melton et al., “Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure,” Circulation, vol. 121, no. 9, pp. 1086–1095, 2010. View at Publisher · View at Google Scholar · View at Scopus
  173. V. M. Conraads, L. Tavazzi, M. Santini et al., “Sensitivity and positive predictive value of implantable intrathoracic impedance monitoring as a predictor of heart failure hospitalizations: the SENSE-HF trial,” European Journal of Heart Failure, vol. 32, pp. 2266–2273, 2011. View at Google Scholar
  174. D. J. van Veldhuisen, F. Braunschweig, V. Conraads et al., “Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure,” Circulation, vol. 124, pp. 1719–1726, 2011. View at Google Scholar
  175. W. T. Abraham, P. B. Adamson, R. C. Bourge et al., “Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial,” The Lancet, vol. 377, no. 9766, pp. 658–666, 2011. View at Publisher · View at Google Scholar · View at Scopus
  176. S. Yusuf, M. A. Pfeffer, K. Swedberg et al., “Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial,” The Lancet, vol. 362, no. 9386, pp. 777–781, 2003. View at Publisher · View at Google Scholar · View at Scopus
  177. J. G. F. Cleland, M. Tendera, J. Adamus, N. Freemantle, L. Polonski, and J. Taylor, “The perindopril in elderly people with chronic heart failure (PEP-CHF) study,” European Heart Journal, vol. 27, no. 19, pp. 2338–2345, 2006. View at Publisher · View at Google Scholar · View at Scopus
  178. B. M. Massie, P. E. Carson, J. J. McMurray et al., “Irbesartan in patients with heart failure and preserved ejection fraction,” The New England Journal of Medicine, vol. 359, no. 23, pp. 2456–2467, 2008. View at Publisher · View at Google Scholar · View at Scopus
  179. A. S. Desai, E. F. Lewis, R. Li et al., “Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction,” American Heart Journal, vol. 162, pp. 966–972.e10, 2011. View at Publisher · View at Google Scholar
  180. K. A. Ammar, S. J. Jacobsen, D. W. Mahoney et al., “Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community,” Circulation, vol. 115, no. 12, pp. 1563–1570, 2007. View at Publisher · View at Google Scholar · View at Scopus
  181. D. J. Campbell, “Heart failure: how can we prevent the epidemic?” Medical Journal of Australia, vol. 179, no. 8, pp. 422–425, 2003. View at Google Scholar · View at Scopus
  182. M. R. Law, J. K. Morris, and N. J. Wald, “Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies,” British Medical Journal, vol. 338, article b1665, 2009. View at Publisher · View at Google Scholar · View at Scopus
  183. K. Wilson, N. Gibson, A. Willan, and D. Cook, “Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies,” Archives of Internal Medicine, vol. 160, no. 7, pp. 939–944, 2000. View at Google Scholar · View at Scopus
  184. B. Mihaylova, J. Emberson, L. Blackwell et al., “The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials,” The Lancet, vol. 380, pp. 581–590, 2012. View at Google Scholar
  185. C. Baigent, A. Keech, P. M. Kearney et al., “Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins,” The Lancet, vol. 366, pp. 1267–1278, 2005. View at Google Scholar
  186. T. J. Wang, J. C. Evans, E. J. Benjamin, D. Levy, E. C. LeRoy, and R. S. Vasan, “Natural history of asymptomatic left ventricular systolic dysfunction in the community,” Circulation, vol. 108, no. 8, pp. 977–982, 2003. View at Publisher · View at Google Scholar · View at Scopus
  187. S. J. Lord, L. Irwig, and R. J. Simes, “When is measuring sensitivity and specificity sufficient to evaluate a diagnostic test, and when do we need randomized trials?” Annals of Internal Medicine, vol. 144, no. 11, pp. 850–855, 2006. View at Google Scholar · View at Scopus
  188. T. A. McDonagh, C. E. Morrison, A. Lawrence et al., “Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population,” The Lancet, vol. 350, no. 9081, pp. 829–833, 1997. View at Publisher · View at Google Scholar · View at Scopus
  189. H. Schunkert, U. Broeckel, H. W. Hense, U. Keil, and G. A. Riegger, “Left-ventricular dysfunction,” The Lancet, vol. 351, no. 9099, p. 372, 1998. View at Google Scholar · View at Scopus
  190. A. Mosterd, A. W. Hoes, M. C. De Bruyne et al., “Prevalence of heart failure and left ventricular dysfunction in the general population. The Rotterdam Study,” European Heart Journal, vol. 20, no. 6, pp. 447–455, 1999. View at Publisher · View at Google Scholar · View at Scopus
  191. M. K. Davies, F. D. R. Hobbs, R. C. Davis et al., “Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study,” The Lancet, vol. 358, no. 9280, pp. 439–444, 2001. View at Publisher · View at Google Scholar · View at Scopus
  192. R. B. Devereux, M. J. Roman, M. Paranicas et al., “A population-based assessment of left ventricular systolic dysfunction in middle-aged and older adults: the Strong Heart Study,” American Heart Journal, vol. 141, no. 3, pp. 439–446, 2001. View at Publisher · View at Google Scholar · View at Scopus
  193. M. M. Redfield, S. J. Jacobsen, J. C. Burnett, D. W. Mahoney, K. R. Bailey, and R. J. Rodeheffer, “Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic,” Journal of the American Medical Association, vol. 289, no. 2, pp. 194–202, 2003. View at Publisher · View at Google Scholar · View at Scopus
  194. W. P. Abhayaratna, W. T. Smith, T. H. Marwick, I. M. Jeffrey, and D. A. McGill, “Prevalence of heart failure and systolic ventricular dysfunction in older Australians: the Canberra heart study,” Medical Journal of Australia, vol. 184, no. 4, pp. 151–154, 2006. View at Google Scholar · View at Scopus
  195. K. Bibbins-Dorningo, M. J. Pletcher, F. Lin et al., “Racial differences in incident heart failure among young adults,” The New England Journal of Medicine, vol. 360, no. 12, pp. 1179–1190, 2009. View at Publisher · View at Google Scholar · View at Scopus
  196. G. I. W. Galasko, S. C. Barnes, P. Collinson, A. Lahiri, and R. Senior, “What is the most cost-effective strategy to screen for left ventricular systolic dysfunction: natriuretic peptides, the electrocardiogram, hand-held echocardiography, traditional echocardiography, or their combination?” European Heart Journal, vol. 27, no. 2, pp. 193–200, 2006. View at Publisher · View at Google Scholar · View at Scopus
  197. L. L. Ng, B. Pathik, I. W. Loke, I. B. Squire, and J. E. Davies, “Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure,” American Heart Journal, vol. 152, no. 1, pp. 94–101, 2006. View at Publisher · View at Google Scholar · View at Scopus
  198. E. C. Vourvouri, A. F. L. Schinkel, J. R. T. C. Roelandt et al., “Screening for left ventricular dysfunction using a hand-carried cardiac ultrasound device,” European Journal of Heart Failure, vol. 5, no. 6, pp. 767–774, 2003. View at Publisher · View at Google Scholar · View at Scopus
  199. L. L. Ng, I. W. Loke, J. E. Davies et al., “Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides,” Journal of the American College of Cardiology, vol. 45, no. 7, pp. 1043–1050, 2005. View at Publisher · View at Google Scholar · View at Scopus
  200. M. M. Redfield, R. J. Rodeheffer, S. J. Jacobsen, D. W. Mahoney, K. R. Bailey, and J. C. Burnett Jr., “Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study,” Circulation, vol. 109, no. 25, pp. 3176–3181, 2004. View at Google Scholar · View at Scopus
  201. P. A. Heidenreich, M. A. Gubens, G. C. Fonarow, M. A. Konstam, L. W. Stevenson, and P. G. Shekelle, “Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction,” Journal of the American College of Cardiology, vol. 43, no. 6, pp. 1019–1026, 2004. View at Publisher · View at Google Scholar · View at Scopus
  202. J. Latour-Pérez, F. J. Coves-Orts, C. Abad-Terrado, V. Abraira, and J. Zamora, “Accuracy of B-type natriuretic peptide levels in the diagnosis of left ventricular dysfunction and heart failure: a systematic review,” European Journal of Heart Failure, vol. 8, no. 4, pp. 390–399, 2006. View at Publisher · View at Google Scholar · View at Scopus
  203. B. Ewald, D. Ewald, A. Thakkinstian, and J. Attia, “Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction,” Internal Medicine Journal, vol. 38, no. 2, pp. 101–113, 2008. View at Publisher · View at Google Scholar · View at Scopus
  204. C. Davenport, E. Y. L. Cheng, Y. T. T. Kwok et al., “Assessing the diagnostic test accuracy of natriuretic peptides and ECG in the diagnosis of left ventricular systolic dysfunction: a systematic review and meta-analysis,” British Journal of General Practice, vol. 56, no. 522, pp. 48–56, 2006. View at Google Scholar · View at Scopus
  205. R. S. Vasan, E. J. Benjamin, M. G. Larson et al., “Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study,” Journal of the American Medical Association, vol. 288, no. 10, pp. 1252–1259, 2002. View at Google Scholar · View at Scopus
  206. V. Madhok, G. Falk, A. Rogers, A. D. Struthers, F. M. Sullivan, and T. Fahey, “The accuracy of symptoms, signs and diagnostic tests in the diagnosis of left ventricular dysfunction in primary care: a diagnostic accuracy systematic review,” BMC Family Practice, vol. 9, article 56, 2008. View at Publisher · View at Google Scholar · View at Scopus
  207. T. A. McDonagh, S. Holmer, I. Raymond, A. Luchner, P. Hildebrant, and H. J. Dargie, “NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies,” European Journal of Heart Failure, vol. 6, no. 3, pp. 269–273, 2004. View at Publisher · View at Google Scholar · View at Scopus
  208. J. J. Atherton, “Screening for left ventricular systolic dysfunction: is imaging a solution?” JACC Cardiovascular Imaging, vol. 3, no. 4, pp. 421–428, 2010. View at Publisher · View at Google Scholar · View at Scopus
  209. F. Yousaf, J. Collerton, A. Kingston et al., “Prevalence of left ventricular dysfunction in a UK community sample of very old people: the Newcastle 85+ study,” Heart, vol. 98, pp. 1418–1423, 2012. View at Publisher · View at Google Scholar
  210. M. McGrady, H. Krum, M. J. Carrington et al., “Heart failure, ventricular dysfunction and risk factor prevalence in Australian Aboriginal peoples: the Heart of the Heart Study,” Heart, vol. 98, no. 21, pp. 1562–1567, 2012. View at Google Scholar
  211. R. Kelly and A. D. Struthers, “Screening for left ventricular systolic dysfunction in patients with stroke, transient ischaemic attacks, and peripheral vascular disease,” QJM: Monthly Journal of the Association of Physicians, vol. 92, no. 6, pp. 295–297, 1999. View at Google Scholar · View at Scopus
  212. M. A. Silver and C. Pisano, “High incidence of elevated B-type natriuretic peptide levels and risk factors for heart failure in an unselected at-risk population (stage A): implications for heart failure screening programs,” Congestive Heart Failure, vol. 9, no. 3, pp. 127–132, 2003. View at Google Scholar · View at Scopus
  213. L. J. Boonman-de Winter, F. H. Rutten, M. J. Cramer et al., “High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes,” Diabetologia, vol. 55, pp. 2154–2162, 2012. View at Publisher · View at Google Scholar
  214. M. Nakamura, H. Endo, M. Nasu, N. Arakawa, T. Segawa, and K. Hiramori, “Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population,” Heart, vol. 87, no. 2, pp. 131–135, 2002. View at Google Scholar · View at Scopus
  215. G. I. W. Galasko, A. Lahiri, and R. Senior, “Portable echocardiography: an innovative tool in screening for cardiac abnormalities in the community,” European Journal of Echocardiography, vol. 4, no. 2, pp. 119–127, 2003. View at Publisher · View at Google Scholar · View at Scopus
  216. Y. Takemoto, M. E. Barnes, J. B. Seward et al., “Usefulness of left atrial volume in predicting first congestive heart failure in patients < or = 65 years of age with well-preserved left ventricular systolic function,” American Journal of Cardiology, vol. 96, no. 6, pp. 832–836, 2005. View at Publisher · View at Google Scholar · View at Scopus
  217. G. P. Aurigemma, J. S. Gottdiener, L. Shemanski, J. Gardin, and D. Kitzman, “Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study,” Journal of the American College of Cardiology, vol. 37, no. 4, pp. 1042–1048, 2001. View at Publisher · View at Google Scholar · View at Scopus
  218. D. A. Duprez, N. Florea, W. Zhong et al., “Vascular and cardiac functional and structural screening to identify risk of future morbid events: preliminary observations,” Journal of the American Society of Hypertension, vol. 5, pp. 401–409, 2011. View at Publisher · View at Google Scholar · View at Scopus
  219. P. S. Douglas, A. Taylor, D. Bild et al., “Outcomes research in cardiovascular imaging report of a workshop sponsored by the national heart, lung, and blood institute,” Circulation, vol. 2, no. 4, pp. 339–348, 2009. View at Publisher · View at Google Scholar · View at Scopus